NaturalNews.com

Back in the early 2000s, the FDA launched the Safety First Steering Committee (SFSC). It was started to address the safety concerns of marketed drugs of noteworthy concern to Americans. Today, the acronym is still found ubiquitously throughout FDA documents, but those links no longer function.

(Article by David Gortler republished from Brownstone.org)

It appears to have been replaced by the Drug Risk Management Board (DRMB). The DRMB has no public-facing web page, but it appears that the DRMB is just a rebranded SFSC.

Per the FDA:

“The DRMB is a cross-CDER governance board responsible for three key objectives: (1) facilitating and coordinating decisions around major product safety issues, (2) providing clear and consistent guidance enabling an appropriate response to major safety issues, and (3) systematically communicating decisions and resulting actions across the Center and to other stakeholders as appropriate. In addition, the DRMB facilitates and coordinates all new and existing marketed product-safety initiatives.”

The Drug Safety Monitoring Board was chaired by Dr. Patrizia Cavazzoni, the head of the FDA’s Center for Drug Evaluation and Research (CDER). Cavazzoni unexpectedly resigned just hours prior to Donald Trump’s inauguration on Jan 20th, 2025.

TheGatewayPundit.com

A group of high school students from Centreville High School in Virginia, in collaboration with the FDA, has uncovered alarming DNA contamination in both Pfizer’s experimental and commercial mRNA COVID-19 shots.

Their peer-reviewed study, published in the Journal of High School Science on December 29th, has sparked renewed debate over vaccine manufacturing standards and quality control processes.

The researchers, led by Tyler Wang, Alex Kim, and Kevin Kim, developed a novel method to detect replication-competent DNA impurities at FDA’s own research facility at the White Oak Campus, Children’s Health Defense reported.

Their technique involves extracting DNA from vaccine samples, ligating it into a circular form, and then transforming it into Escherichia coli cells.

AharylAttkisson.com

Advisers to the FDA recently met to discuss the future of respiratory syncytial virus (RSV) vaccines for children. This followed Moderna’s forced halt of its mRNA RSV vaccine trials after alarming data showed higher rates of severe RSV in vaccinated infants compared to those given a placebo. Clinical trial data revealed 12.5% of vaccinated children developed severe RSV disease, compared to just 5% in the placebo group.

These outcomes raised alarms due to past experiences with RSV vaccines. In the 1960s, trials of a formalin-inactivated RSV vaccine led to vaccine-associated enhanced respiratory disease (VAERD), where vaccination worsened illness instead of preventing it. That trial resulted in two toddler deaths and hospitalization for 80% of the vaccinated participants. Despite decades of research, the risks tied to VAERD remain unresolved.

FDA advisers emphasized the “unmet need” for pediatric RSV vaccines, framing RSV as a leading cause of infant hospitalizations in the US annually. Vaccine makers, spurred by a projected $13.59 billion global RSV vaccine market by 2030, are developing 26 RSV vaccines or monoclonal antibodies for all age groups.

TheGatewayPundit.com

The United States District Court for the Northern District of Texas ruled against the Food and Drug Administration (FDA) in a high-profile case brought by the Public Health and Medical Professionals for Transparency (PHMPT).

The decision mandates the FDA to release the Emergency Use Authorization (EUA) file for the Pfizer-BioNTech COVID-19 vaccine no later than June 30, 2025.

The case stemmed from a Freedom of Information Act (FOIA) request by the PHMPT, which sought comprehensive data related to the Pfizer-BioNTech COVID-19 vaccine.

The FDA initially claimed it would need up to 75 years to process and release the requested documents. However, the Court, presided over by Judge Mark Pittman, rejected this argument, citing the importance of government accountability.

Infowars.com

Clinical trials — funded by the U.S. government and the Bill & Melinda Gates Foundation — are set to begin for a self-amplifying mRNA vaccine targeting the H5N1 bird flu virus.

Arcturus Therapeutics announced earlier this week that the U.S. Food and Drug Administration (FDA) issued a “Study Can Proceed” notification for its investigational ARCT-2304 vaccine candidate.

Epidemiologist Nicolas Hulscher told The Defender the FDA’s notification “means Arcturus Therapeutics can begin its “experiment of injecting humans with H5N1 bird flu replicon mRNA.”

Self-amplifying mRNA injections contain an enzyme that instructs the body on how to make more mRNA. Arcturus says the vaccine is “formulated within a lipid nanoparticle” and “is designed to make many copies of mRNA within the host cell.” This enables “lower doses than conventional mRNA vaccines.”

Hulscher said the replication machinery of self-amplifying vaccines behaves “like a synthetic virus” and “allows for an unknown period of toxic antigen production.”

Writing on Substack, immunologist and biochemist Jessica Rose, Ph.D., said the new vaccine has “major red flags.” She told The Defender, “Self-amplifying mRNA products should not be used. This is an absolute disaster waiting to happen.”

Infowars.com

On August 29 the FDA approved for use in the U.S. a vaccine [ACAM2000] for Monkeypox. While the injection is actually a Smallpox vaccine initially approved in 2007, this new approval allows the shot to be injected into those at ‘high risk’ for the Monkeypox disease, such as those in the LGBTQIAAP2S+ community. It carries with it serious side effect risks, including death to those who have contact with the vaccinated.

“…the FDA approved a new indication for ACAM2000 [the vaccine], to include the prevention of mpox disease in individuals determined to be at high risk for mpox infection. ACAM2000 has been approved since 2007 for the prevention of smallpox disease in individuals determined to be at high risk for smallpox infection. ACAM2000 is a live replicating vaccinia virus vaccine,” an FDA press release said on August 30.

The medication guide found on the FDA’s website for the vaccine lists numerous serious side effects on page 1.

Nathan Jones, CEO of Xlear Inc., exposes yet another inexpensive and effective early treatment that the CDC, FTC, and FDA suppressed in order to push toxic and ineffective vaccines which resulted in tens of thousands of preventable deaths. 
 

If the video won't play please report the problem by clicking here.
__

TheDailySignal.com

A team leader at the U.S. Food and Drug Administration recommended approving “puberty blockers” for teens who identify as transgender even while noting that a recent study showed these drugs are associated with an “increased risk in depression and suicidality.”

Many activists claim that children struggling with gender dysphoria (the persistent condition of identifying with the gender opposite their biological sex) must receive experimental drugs to make their bodies resemble bodies of the opposite sex to stop them from committing suicide, yet the FDA study suggested these drugs actually increase the risk of suicide.

According to an internal email obtained by The BMJ, the FDA told a departing staffer who had reviewed
COVID-19 vaccines while working at the FDA and who later accepted a job at Moderna that he could still work
“behind the scenes” to influence agency decision-making.

ChildrensHealthDefense.org

The U.S. Food and Drug Administration (FDA) informs departing workers that they can still influence the agency’s decision-making after leaving their position to work for the pharmaceutical industry, a new investigation by The BMJ revealed.

According to an internal email obtained by The BMJ, the FDA told departing staffer Doran Fink, M.D., Ph.D. — who had reviewed COVID-19 vaccines while working at the FDA and who had accepted a job at Moderna — that although U.S. law prohibits some forms of lobbying contact between former FDA workers who leave to join the private sector, they “do not prohibit the former employee from other activities, including working ‘behind the scenes.’”

TheEpochTimes.com

As spring gardening approaches, a new contender has entered the fray—the genetically modified (GM) Purple Tomato. Unlike its GM predecessors, the GM Purple Tomato is not destined solely for the fields of commercial agriculture—it has made its debut in the backyards of home gardeners across the United States.

With claims of heightened antioxidant levels and potential health benefits, this novel creation has stirred both excitement and controversy among consumers and scientists alike. Biotech investors hope it can usher in a new era of public trust in genetically engineered foods while skeptics worry the tomatoes’ near-total lack of regulation or review may hide dangers to human health and/or the environment.